Low-dose colchicine to lower risk in leg artery disease
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re over 18 years old
- You have symptomatic peripheral artery disease in a leg, like painful walking limits, rest pain/foot wounds, or loss of tissue (gangrene/necrosis)
- Tests show poor leg blood flow or artery narrowing (ABI ≤ 0.90, or toe pressure/index if ankle arteries can’t be compressed)
- You’ve had a recent blood-flow procedure or amputation for artery disease, or you currently have severe symptoms like rest pain or tissue loss
- You can agree to join the study and return for follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a low-dose colchicine (LoDoCo) can help people with heart failure and inflammation feel better and exercise more. It is for adults 50 and older with HFpEF who have signs of inflammation in their blood.
This study tests whether a medication called colchicine can help prevent amputation in people with severe leg blood flow problems who just had surgery or a catheter procedure to restore blood flow. Colchicine is an anti-inflammatory drug that may help protect the leg tissue after treatment.
This trial tests if a low dose of colchicine, a medicine that reduces inflammation, can help improve blood vessel and bone health in people with moderate chronic kidney disease.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial tests whether taking colchicine can prevent coronary artery disease (heart artery blockages) in people who have several heart risk factors but do not already have diagnosed disease. It aims to see if colchicine lowers the chance of developing heart artery problems over time.
This trial tests whether adding a targeted anti-inflammatory drug to standard care can prevent future heart attacks or strokes in people with high-risk chronic coronary artery disease. It is for people who have a moderate narrowing in a heart artery with a vulnerable plaque and signs of inflammation.
Hear when a new Peripheral Arterial Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.